Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Table 5 Factors associated with failure to achieve sustained virologic response by intention-to-treat analysis

Variable	Univariate analysis
	OR	95%CI	P value
Age	1.003	0.974-1.033	0.8349
Men	1.811	0.814-4.030	0.1458
High-blood pressure	1.029	0.530-1.999	0.9328
Type 2 diabetes	0.837	0.396-1.767	0.6400
BMI	1.024	0.954-1.099	0.5120
Dyslipidemia	1.851	0.902-3.800	0.0934
Hypothyroidism	1.416	0.626-3.206	0.4036
Psychiatric disorder	1.076	0.366-3.165	0.8940
Previous alcohol use	2.026	0.985-4.167	0.0551
Presence of cirrhosis	1.726	0.854-3.486	0.1281
Liver-related complications
Ascites	1.356	0.612-3.003	0.4526
Esophageal varices	2.381	1.137-4.988	0.0215a
Portal hypertensive bleeding	2.756	1.173-6.471	0.0200a
Hepatic encephalopathy	4.320	1.920-9.721	0.0004a
AST	1.006	1.000-1.012	0.0707
ALT	1.003	0.999-1.007	0.1402
Total bilirubin	1.085	0.846-1.392	0.5198
Albumin	0.528	0.322-0.867	0.0115a
Platelets	1.000	1.000-1.000	0.3813
INR	5.542	2.023-15.182	0.0009a
Creatinine	1.117	1.056-1.312	0.0033a
Hemoglobin	0.975	0.818-1.161	0.7741
Alpha-fetoprotein	0.995	0.980-1.010	0.5055
Child-Pugh score	1.166	0.901-1.511	0.2431
MELD score	1.143	1.060-1.233	0.0005a
Ribavirin dose	0.996	0.832-1.192	0.9614
Treatment duration	1.024	0.962-1.090	0.4563

^aP value < 0.05. Univariate logistic regression. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; HCV: Hepatitis C virus; INR: International normalized ratio; MELD: Model for end-stage liver disease; OR: Odds ratio; SVR: Sustained virologic response.